Rubbing my ball, page-922

Well we didn't push past 50c but got there for a brief moment

But it doesn't really matter.

Thinking on how Imugene have patented the Her-VAXX tech in Japan, why would you go to the trouble of doing so at this stage of its trials? The answer seems pretty obvious. Because they know it works, and there will be a deal very shortly. They're positioning themselves and protecting the IP before it's released to the joy of all those who will benefit.

And to think, PD1 and CF33 are yet to really come into their own. It is not hard to see why the SP has been surging the way it has, regardless of entering the ASX300.

Of course these are just the musings of a layman. But if intuition serves, I reckon the above would be pretty right. Don't quote me tho, this is the ball rub thread